Temporary Suspension
27 Março 2009 - 4:00AM
UK Regulatory
TIDMNIM
RNS Number : 5811P
Norwood Immunology Ld
27 March 2009
NORWOOD IMMUNOLOGY LIMITED
Temporary suspension of trading in securities
Norwood Immunology Limited and its subsidiaries ("Norwood Immunology" or the
"Group") (AIM:NIM), the Group focused on stem cell therapies, the rejuvenation
and repair of the immune system and the development of virosomal vaccines, today
announces that its AIM securities will today be suspended pursuant to the AIM
Rules for Companies as Norwood Immunology will be unable to publish its interim
report for the six months ended 31 December 2008 by 31 March 2009. This has been
as a consequence of the proposed disposal of Bestewil Holdings B.V. and
finalisation of the Group's Annual Report and Accounts for the year ended 30
June 2008 announced on 6 and 10 March 2009 respectively.
A further announcement will be made in due course.
For further information please contact:
+-----------------------------------------------+------------------------+
| Norwood Immunology Limited | |
+-----------------------------------------------+------------------------+
| Richard Williams, Chief Executive Officer | +44 (0)7860 295153 |
+-----------------------------------------------+------------------------+
| | |
+-----------------------------------------------+------------------------+
| KBC Peel Hunt Ltd (NOMAD Adviser and Broker) | +44 (0)207 418 8900 |
+-----------------------------------------------+------------------------+
| Capel Irwin | |
+-----------------------------------------------+------------------------+
| David Anderson | |
+-----------------------------------------------+------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
SUSPUUBAWUPBGRQ
Norwood Immunology (LSE:NIM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Norwood Immunology (LSE:NIM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Norwood Imm. da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Norwood Immunology